Advemto is revolutionising biomarker mapping with its advanced 2D molecular barcode reader, enabling clinical and pharmaceutical labs to identify hundreds of biomarkers simultaneously. Traditional fluorescent labelling methods allow only a few biomarkers to be mapped at once due to limitations in fluorescence distinguishability and interference from natural cell fluorescence. This restriction leads to lengthy, costly processes—up to a year and $2 million per trial—for iterative label panel design.

Advemto’s technology overcomes these limitations, converting blurry fluorescent signals into sharp, distinct 2D barcodes for precise and quantitative biomarker identification. This innovation accelerates drug development and clinical diagnostics, making data merging across trials feasible for the first time.

Based in Wellington, Advemto is led by Prof. Justin Hodgkiss, CEO & CSO, an award-winning research leader and MacDiarmid Institute co-director. Advemto is currently raising seed funding, with Movac leading the round, to accelerate market entry and expand into life sciences.